S-1/A: Aptevo Therapeutics Announces Public Offering of Common Stock and Warrants

Aptevo Therapeutics is launching a public offering to sell up to 8,000,000 shares of common stock, pre-funded warrants, and various series of warrants to raise capital for working capital and general corporate purposes.

Summary

• Aptevo Therapeutics Inc. is undertaking a public offering to sell up to 8,000,000 shares of its common stock.
• The offering includes Series A and Series B warrants, each to purchase up to 8,000,000 and 120,000,000 shares of common stock, respectively.
• Pre-funded warrants are also being offered to purchasers who would otherwise exceed beneficial ownership limitations, exercisable for one share of common stock at $0.0001 per share.
• The assumed combined public offering price is $2.50 per share and associated warrants.
• The Series A and B Warrants will be exercisable beginning on the date of Stockholder Approval.
• The Series A Warrants will expire five years from the date of Stockholder Approval and the Series B Warrants will expire two and a half years from the date of Stockholder Approval.
• Roth Capital Partners, LLC is acting as the exclusive placement agent for the offering.
• The offering is expected to terminate no later than May 15, 2025.
• The company intends to use the net proceeds from this offering for working capital and general corporate purposes, including the further development of our product candidates.

Sentiment

Score: 5

Explanation: The announcement is neutral. It details a capital raising activity, which is neither inherently positive nor negative. The success and impact depend on market conditions and the company's execution.

Positives

• The offering aims to provide Aptevo with additional working capital to fund its clinical programs and general corporate purposes.
• The inclusion of pre-funded warrants allows the company to accommodate investors who might otherwise be restricted by beneficial ownership limitations.
• The engagement of Roth Capital Partners, LLC as placement agent brings expertise in arranging the sale of securities.

Negatives

• The offering may cause immediate and substantial dilution in the net tangible book value per share of the common stock.
• The Series A and Series B Warrants are not exercisable until Stockholder Approval and may not have any value.
• There is no guarantee that the Stockholder Approval will ever be obtained.
• There is no established public trading market for the common warrants or pre-funded warrants, and we do not expect a market to develop.
• This is a reasonable best efforts offering, no minimum amount of securities is required to be sold, and we may not raise the amount of capital we believe is required for our business plans, including our near-term business plans.

Risks

• The company has broad discretion in the use of the net proceeds from this offering and may not use them effectively.
• The price per share, together with the number of shares of our common stock we propose to issue and ultimately will issue if this offering is completed, may result in an immediate decrease in the market price of our common stock.
• If the Series B Warrants are exercised by way of an alternative cashless exercise, stockholders may suffer substantial dilution.
• There is no public market for the common warrants or pre-funded warrants being offered by us in this offering.
• The common warrants and pre-funded warrants are speculative in nature.
• Resales of our common stock in the public market during this offering by our stockholders may cause the market price of our common stock to fall.

Future Outlook

The company intends to use the net proceeds from this offering for working capital to fund our clinical programs and general corporate purposes, including the further development of our product candidates.

Industry Context

Bispecific therapeutics are increasingly recognized as potent anti-cancer agents. Sixteen new bispecific agents have been approved for use by the FDA in the last three years and there is a total of 125 bispecific drug candidates currently in development.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares and warrants.
• The company's employees and consultants may benefit from the continued funding of operations and development programs.
• Customers and partners may see continued progress in the development of Aptevo's product candidates.
• Suppliers and creditors may benefit from the company's improved financial position.

Next Steps

• The company will seek Stockholder Approval for the exercise of the Series A and Series B Warrants.
• The company will file a Prospectus Supplement with the Commission.
• The company will apply to list the Shares and Warrant Shares on the Nasdaq Capital Market.
• The company will use the net proceeds from this offering for working capital to fund our clinical programs and general corporate purposes, including the further development of our product candidates.

Key Dates

Keywords

public offering, common stock, warrants, pre-funded warrants, Aptevo Therapeutics, capital raise, securities, Roth Capital Partners, equity financing, biotechnology